CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on advancing adoptive cell therapy for cancer treatment by developing a high-throughput system for gene modification of T cells and mesenchymal stromal cells using a novel photoporation technology. The aim is to enhance safety and efficiency in cell production while preparing for commercialization.
Adoptive cell therapy has emerged as a promising strategy to treat cancer.
It relies on patient-derived cells, such as T cells and mesenchymal stromal cells (MSCs), which are genetically engineered to become better equipped to fight cancer cells.
While ex vivo genetic modification of T cells and MSCs has traditionally been performed with viral vectors, they come with concerns about safety, sustainable production and high development costs.
Electroporation is a non-viral alternative transfection…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, LEIDEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
